Reolysin (Oncolytics) success in Head and Neck Cancer

A trial called, REO 015, was a single arm open-label, study of Reolysin, from Oncyolytics Biotech, which was given intravenously with paclitaxel (175 mg/m2) and carboplatin (AUC 5) every three weeks in patients with platinum-refractory recurrent and/or metastatic squamous cell cancers of the oral cavity, larynx, or pharynx. Findings were presented at the AACR-NCI-EORTC International Conference on Molecular and Cancer Therapeutics in San Francisco and showed a disease control rate (SD or better) of 46%. This result followed a similar result in a UK trial called REO 11.see Specenier P et al. (2011) Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Am J ClinOncol 34: 472-7.